The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Distribution of apolipoprotein E between free and A-II complexed forms in very-low- and high-density lipoproteins: functional implications
Abstract
The stability of apolipoprotein E/lipoprotein associations has been examined as a function of apolipoprotein E phenotype. Visualisation by immunoblotting showed plasma apolipoprotein E to be present in two forms; the free form and, as previously described, an E-A-II complex. In very low density lipoproteins isolated by gel filtration from subjects with E3/3 and E4/3 phenotypes, apolipoprotein E was present essentially in the free form (ratio free: complex of 12.2 and 37.5, respectively). Exploiting ultracentrifugation as the disruptive agent, very-low-density lipoproteins thus isolated were shown to have substantially lower ratios (5.6 and 5.4, respectively) reflecting preferential loss of free apolipoprotein E. In high-density lipoproteins isolated by gel filtration from E3/3 phenotypes, apolipoprotein E was largely present as an E-A-II complex (80.3%). In contrast, the majority of apolipoprotein E in high-density lipoproteins from E4/3 phenotypes was present in the free form (58.7%). In both phenotypes, the content of free apolipoprotein E was markedly reduced by ultracentrifugation. The results confirm the notion that the formation of the E-A-II complex is a major determinant of the stability of apolipoprotein E-high-density lipoprotein associations. Moreover, that the predominant, ancestral isoform, apolipoprotein E3, exists largely as an E-A-II complex in higher density lipoproteins has important functional implications for this plasma source of apolipoprotein E.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The ApoE-ApoA2 heterodimer has lower affinity to LDLR than ApoE alone.
“The ApoE-ApoA2 heterodimer has lower affinity to LDLR than ApoE alone [137].”
From ApoE lipoproteins in the central nervous system under homeostasis and role in Alzheimer’s disease and related disorders (2026) · cites this paper as [137]
The ApoE-ApoA2 complex is predominant in the HDL fraction of ApoE in plasma, and the ApoE-ApoA2 heterodimer is more stable under ultracentrifugation conditions.
“The ApoE-ApoA2 complex is predominant in the HDL fraction of ApoE in plasma and the ApoE-ApoA2 heterodimer is more stable under ultracentrifugation conditions [137].”
From ApoE lipoproteins in the central nervous system under homeostasis and role in Alzheimer’s disease and related disorders (2026) · cites this paper as [137]
Citations
Cites
Apolipoprotein E polymorphism and atherosclerosis.
Davignon, J., Gregg, R. E., & Sing, C. F. (1988) · Arteriosclerosis: An Official Journal of the American Heart Association, Inc. · doi:10.1161/01.atv.8.1.1 · Cited by 1,981
Lipoprotein receptors in the liver. Control signals for plasma cholesterol traffic.
Brown, M. S., & Goldstein, J. L. (1983) · Journal of Clinical Investigation · doi:10.1172/jci111044 · Cited by 545
Proposed nomenclature of apoE isoproteins, apoE genotypes, and phenotypes
Zannis, V. I., Breslow, J. L., Utermann, G., Mahley, R. W., Weisgraber, K. H., Havel, R. J., Goldstein, J. L., Brown, M. S., Schonfeld, G., Hazzard, W. R., et al. (1982) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)38094-9 · Cited by 436
Flagged first, then by citations
Research works printed but not linked: 42
- Hoeg, 1985, Science, 227, 759, 10.1126/science.2982214 · DOI
- Mahley, 1981, J. Clin. Invest., 68, 1197, 10.1172/JCI110365 · DOI
- Kowal, 1989, 86, 5810
- Mahley, 1988, Science, 240, 622, 10.1126/science.3283935 · DOI · Paper page
- Innerarity, 1984, J. Biol. Chem., 259, 7261, 10.1016/S0021-9258(17)39866-6 · DOI · Paper page
- Blum, 1980, J. Clin. Invest., 66, 1240, 10.1172/JCI109975 · DOI
- Gibson, 1983, J. Lipid Res., 24, 886, 10.1016/S0022-2275(20)37934-7 · DOI
- Castro, 1984, J. Lipid Res., 25, 58, 10.1016/S0022-2275(20)37844-5 · DOI
- Reichl, 1989, Arteriosclerosis, 9, 785, 10.1161/01.ATV.9.6.785 · DOI
- Groot, 1982, J. Lipid Res., 23, 1342, 10.1016/S0022-2275(20)38040-8 · DOI
- James, 1989, Biochim. Biophys. Acta, 1002, 292, 10.1016/0005-2760(89)90343-3 · DOI
- James, 1988, J. Lipid Res., 29, 1557, 10.1016/S0022-2275(20)38408-X · DOI
- Rudel, 1986, Methods Enzymol., 129, 45, 10.1016/0076-6879(86)29061-8 · DOI
- Menzel, 1983, Arteriosclerosis, 3, 310, 10.1161/01.ATV.3.4.310 · DOI
- James, 1987, Schweiz. med. Wschr., 117, 2021
- James, 1980, FEBS Lett., 120, 145, 10.1016/0014-5793(80)81066-0 · DOI
- Ey, 1978, Immunochemistry, 15, 429, 10.1016/0161-5890(78)90070-6 · DOI
- Laemmli, 1970, Nature, 227, 680, 10.1038/227680a0 · DOI · Paper page
- Weisgraber, 1978, J. Biol. Chem., 253, 6281, 10.1016/S0021-9258(17)34612-4 · DOI · Paper page
- Goldstein, 1974, J. Biol. Chem., 249, 5153, 10.1016/S0021-9258(19)42341-7 · DOI · Paper page
- Lowry, 1951, J. Biol. Chem., 193, 265, 10.1016/S0021-9258(19)52451-6 · DOI
- James, 1990, Atherosclerosis, 83, 35, 10.1016/0021-9150(90)90128-6 · DOI
- Bisgaier, 1985, J. Lipid Res., 26, 11, 10.1016/S0022-2275(20)34400-X · DOI
- Innerarity, 1978, J. Biol. Chem., 253, 6289, 10.1016/S0021-9258(17)34613-6 · DOI · Paper page
- Utermann, 1987, Am. Heart J., 113, 433, 10.1016/0002-8703(87)90610-7 · DOI · Paper page
- Imaizumi, 1978, J. Lipid Res., 19, 712, 10.1016/S0022-2275(20)41271-4 · DOI
- Marcel, 1983, Biochim. Biophys. Acta, 750, 411, 10.1016/0005-2760(83)90047-4 · DOI
- Swift, 1984, J. Lipid Res., 25, 1, 10.1016/S0022-2275(20)37847-0 · DOI
- Dolphin, 1986, Biochim. Biophys. Acta, 875, 21, 10.1016/0005-2760(86)90006-8 · DOI
- Marcel, 1981, J. Lipid Res., 22, 1198, 10.1016/S0022-2275(20)37312-0 · DOI
- Falko, 1980, J. Clin. Endocrinol. Metab., 50, 521, 10.1210/jcem-50-3-521 · DOI
- McLean, 1983, J. Biol. Chem., 258, 8993, 10.1016/S0021-9258(18)32155-0 · DOI
- Chapman, 1986, Methods Enzymol., 128, 70, 10.1016/0076-6879(86)28063-5 · DOI
- Utermann, 1980, Eur. J. Biochem., 107, 225, 10.1111/j.1432-1033.1980.tb04643.x · DOI
- Blum, 1982, J. Lipid Res., 23, 1308, 10.1016/S0022-2275(20)38036-6 · DOI
- Hamilton, 1976, J. Clin. Invest., 58, 667, 10.1172/JCI108513 · DOI
- Glomset, 1980, Ann. NY Acad. Sci., 348, 224, 10.1111/j.1749-6632.1980.tb21303.x · DOI
- Mitchell, 1980, J. Lipid Res., 21, 625, 10.1016/S0022-2275(20)42233-3 · DOI
- Cheung, 1984, J. Biol. Chem., 259, 12201, 10.1016/S0021-9258(20)71339-6 · DOI
- Gibson, 1985, Biochim. Biophys. Acta, 835, 113, 10.1016/0005-2760(85)90037-2 · DOI
- Weisgraber, 1986, Methods Enzymol., 128, 145, 10.1016/0076-6879(86)29067-9 · DOI · Paper page
- Steinmetz, 1989, Arteriosclerosis, 9, 405, 10.1161/01.ATV.9.3.405 · DOI · Paper page
Cited by
Sorted by citations
Strickland, M. R., & Holtzman, D. M. (2026) · Molecular Neurodegeneration · doi:10.1186/s13024-026-00970-0
Metadata
- Authors
- Borghini, I., James, R. W., Blatter, M.-C., & Pometta, D.
- Venue
- Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism
- Publisher
- Elsevier BV
- Published
- 1991-05
- Volume
- 1083
- Issue
- 2
- Pages
- 139-146
- ISSN
- 0005-2760
- Cited by
- 21
- References
- 3
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review